Biohaven Ltd.
BHV-1300
Graves' Disease
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for BHV-1300 in Graves' Disease are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“The Company intends to initiate a pivotal study with BHV-1300 in Graves' disease in the second half of 2026.”